Characterized Oral Desensitization Immunotherapy (CODIT™)
Using a standardized approach to oral immunotherapy (OIT) to treat food allergies, starting with peanut allergy.
Research has shown that delivering food allergy treatment through the gut/gastrointestinal tract enables people to build up a level of tolerance against potential reactions due to accidental exposures.
Building on a century of OIT research, Aimmune’s investigational CODIT™ platform is now being used as a standardized approach to treat food allergies, starting with peanut allergy. CODIT™ is being developed with three key elements:
- A standardized OIT protocol with precise oral dosing
- GMP–grade pharmaceutical products
- Training and education
Our unique platform involves patients ingesting controlled, increasing amounts of allergen protein. Over time, the patient’s immune system begins to tolerate larger amounts of the allergen. Those levels are then maintained with a consistent therapeutic dose.
Using our investigational CODIT™ platform and associated pharmaceutical products, we seek to help people with food allergies reduce the risk of life-threatening reactions due to accidental exposure to food allergens.